Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Travera Inc
OncoC4, Inc.
Regeneron Pharmaceuticals
Sotio Biotech Inc.
Exelixis
Mayo Clinic
ViroMissile, Inc.
Seagen Inc.
Daiichi Sankyo
OHSU Knight Cancer Institute
DualityBio Inc.
Jonsson Comprehensive Cancer Center
MacroGenics
City of Hope Medical Center
xCures
Grey Wolf Therapeutics
Jiangsu Simcere Pharmaceutical Co., Ltd.
Zhejiang University
AbbVie
ImmunityBio, Inc.
Ocellaris Pharma, Inc.
Elephas
University of Pittsburgh
Degron Therapeutics Co.
Mayo Clinic
NeoTX Therapeutics Ltd.
AccSalus Biosciences, Inc.
West China Hospital
DualityBio Inc.
Massive Bio, Inc.
HiFiBiO Therapeutics
Incyte Corporation
Incyte Corporation
Exelixis
Incyte Corporation
Merck Sharp & Dohme LLC
Jonsson Comprehensive Cancer Center
Incyte Corporation
Incyte Corporation
Telix Pharmaceuticals (Innovations) Pty Limited
UNICANCER
AbbVie
Arbeitsgemeinschaft medikamentoese Tumortherapie
Bristol-Myers Squibb
Kymab Limited
SOLTI Breast Cancer Research Group
Cofactor Genomics, Inc.
University of Pittsburgh
University of Michigan Rogel Cancer Center